John Mascola, ModeX Therapeutics CSO

Ex-Warp Speed vac­cine leader nabs NextGen funds for Mod­eX Ther­a­peu­tics’ Covid-19 an­ti­bod­ies

A for­mer leader of Op­er­a­tion Warp Speed’s vac­cines ef­fort, which led to a quick roll­out of Covid jabs, is get­ting fed­er­al fund­ing for his biotech’s work on the next gen­er­a­tion of Covid ther­a­peu­tics.

As part of the US gov­ern­ment’s $5 bil­lion Project NextGen, John Mas­co­la’s Mod­eX Ther­a­peu­tics will re­ceive an ini­tial $59 mil­lion to get a mul­ti­spe­cif­ic an­ti­body in­to and through a Phase I tri­al as a po­ten­tial tool for thwart­ing fu­ture SARS-CoV-2 vari­ants. Mas­co­la joined the OP­KO Health-owned Mod­eX in 2022 as chief sci­en­tif­ic of­fi­cer af­ter steer­ing Warp Speed’s vac­cine work and serv­ing as di­rec­tor of the NIH’s Vac­cine Re­search Cen­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.